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Introduction
The notion of pharmaceutical security was addressed 
for the first time, in the Republic of Moldova, in 2009, in a 
report by the Ministry of Health [6], but it should be men-
tioned that, in that case, the Ministry only related the results 
of activities to:
– Ensuring the access of the population to drugs, poin-
ting out certain procedures (price analysis, drugs com-
pensation, centralized procurement);
– Promotion of reasonable use of drugs;
– Development and promotion of the local drug manu-
facturer.
The report presented by the Ministry of Health lacked a 
systemic or, at least, many-sided approach to the pharma-
ceutical security notion. Consequently, the reports of the 
Ministry of Health did not include the chapter on “pharma-
ceutical security”.
The issues related to ensuring the pharmaceutical se-
curity started being addressed nationwide from the year of 
2015 [1].
The Government of the Republic of Moldova regularly 
started addressing various aspects of the pharmaceutical se-
curity [2, 4, 5].
At the same time, it is worthwhile mentioning that gov-
ernment talks are limited to certain aspects of pharmaceuti-
cal safety, without taking into account the systemic nature of 
this area of security [1]. To improve the situation, it is nec-
essary to analyze the legal basis relating to pharmaceutical 
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security of the state and of each citizen. The results of such 
analysis would create grounds for notifying the state authori-
ties on the need to strengthen, in all of its aspects, and not 
partially, the pharmaceutical security.   
The specialized literature did not offer works on the anal-
ysis of the state pharmaceutical security legislation, this fact, 
in tandem with the aforementioned circumstances, features 
the topicality of the issue being addressed. 
The objective of this article is to highlight the legislative 
gaps affecting the pharmaceutical security of the Republic of 
Moldova.
Material and methods
In order to achieve the determined objective, all the leg-
islative and normative acts, directly or indirectly regulating 
the pharmaceutical security, have been initially selected.
The systematization of legal and normative acts has been 
performed based on the following two principles:
I – law/legislation: pharmaceutical, medical, and other 
fields;
II – subsystems of the pharmaceutical safety system [1]: 
a) effectiveness, harmlessness and quality of drugs, b) avail-
ability of drugs, c) quality of pharmaceutical services and the 
smooth operation of the pharmaceutical system.
The list of all legislative and normative acts defining rules 
aimed at ensuring the pharmaceutical security includes 112 
documents, among which: pharmaceutical – 78, medical – 
26, other areas – 8.
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Development of the analytical method
As a methodical tool for highlighting the level of legisla-
tive and normative coverage of the pharmaceutical security, 
the following algorithm was developed:
Step I
Determining, based on a logical analysis, all conditions, 
the compliance with which would ensure the pharmaceu-
tical security of the state and of each citizen. This analysis 
should take into account the de facto situation of the phar-
maceutical system.
Pursuant to the content analysis of the legislation and of 
the sub-legislative acts, as well as taking into consideration 
the national and international practice, the advanced experi-
ence in the field of pharmaceutical security, the conditions 
for ensuring this security were systematized  and grouped 
according to the 2nd systematization principle (tab.1).
The total number of conditions necessary to ensure 
the pharmaceutical security shall be marked by (Cn). The 
number of necessary conditions can be determined as the to-
tal conditions (Cn) or the aggregate of conditions to ensure 
pharmaceutical security directions: 
Cqd – conditions for ensuring the quality, the effective-
ness and the harmlessness of drugs; 
Cad – conditions for ensuring the (physical and economic) 
availability  of drugs; 
Cqa – conditions for ensuring the quality of the pharma-
ceutical act.
Step II
Highlighting of the existence / absence of legal provi-
sions legalizing the application of various ways, methods, 
processes, procedures, regulations and other measures that 
would impose compliance with conditions necessary for 
pharmaceutical security.
Highlighting of the existence / absence of legal provi-
sions aimed at ensuring the pharmaceutical security was 
performed by applying the expertise method combined with 
the Delphi method [3].
For this purpose a panel of experts was created randomly, 
representing:
– the Parliament of the Republic of Moldova;
– the Government of the Republic of Moldova;
– the Ministry of Health;
– the Medicines and Medical Devices Agency;
– Specialized pharmacy chairs of the SUMPh ”Nicolae 
Testemițanu”;
– Pharmacists Association of the Republic of Moldova;
– Local drug manufacturers;
– Pharmaceutical storehouses;
– Drugstores: community (private and network) and 
hospital drugstores.
Therefore, the panel of experts numbered 15 members, 
each of which was provided with a questionnaire to assess 
the compliance with the conditions of ensuring the legisla-
tive coverage for pharmaceutical security (tab. 1) [1], as well 
as the method of assessing the legislative coverage:
– Existence of the necessary legal provision – 1 point;
– Absence of the legal provision – 0 points;
– Existence of the necessary legal provision, but failure to 
comply with – 0.5 points;
– Inefficiency of the regulation for providing the phar-
maceutical security – 0.5 points.
The legislative coverage of conditions for providing the 
pharmaceutical security shall be marked as:
(Pe) – existing legal provisions aimed at ensuring the 
compliance with the conditions necessary, in their turn, to 
provide the pharmaceutical security. Indicator (Pe), as well 
as (Cqa) may be highlighted for the total number of existing 
rules or for the directions of pharmaceutical security provi-
sion:
Peqd – effective legal provisions covering the conditions 
of pharmaceutical security provision by ensuring the quality, 
the efficiency and the harmlessness of drugs.
Pead – effective legal provisions ensuring the physical 
and economic availability of drugs;
Peqa – effective legal provisions ensuring the quality of 
the pharmaceutical act. 
Step III
Determining the degree of legislative coverage of re-
quirements for pharmaceutical safety provision. This in-
dicator shall be marked as (LCp) – for the total number of 
existing legal provisions and necessary conditions, and for 
the three directions for providing pharmaceutical security, 
accordingly: 
LCqd = Peqd / Cqd  (1) – indicator of legislative cov-
erage of pharmaceutical security provision by ensuring the 
quality, efficiency and harmlessness of drugs;
LCad = Pead / Cad     (2) – indicator of legislative cov-
erage of pharmaceutical security provision by ensuring the 
physical and economic availability  of drugs; 
LCqa = Peqa / Cqa      (3) – indicator of legislative cov-
erage of pharmaceutical security provision by ensuring the 
quality of the pharmaceutical act.
Step IV
Development of the quantification scale for the degree 
of legislative coverage for the pharmaceutical security provi-
sion. Taking into consideration that the value of indicator 
(ALn) may vary between ”zero” and ”1”, we undertook to 
develop a clear assessment scale.
For a clearer perception of the indicator ALn, it was pro-
posed to multiply its value by 10, thus, the indicator ampli-
tude will fall in the range of 1-10. For the quantification, the 
following appreciation scale was suggested:
LCp = 0 - null; 
LCp = > 0 … 2 – vulnerable;
LCp = > 2 ... 5 – insufficient;
LCp = > 5 ... 8 – moderate;
LCp  = >  8 …< 10 – good;
LCp = 10 – total. 
Therefore, the final formula for computing the degree 
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of legislative coverage for the state pharmaceutical security 
provision (LCp) is as follows:
LCp = Pe x  10  (4),  Cn
in which:
Pe – the number of existing legal provisions aimed at 
pharmaceutical security provision;
Cn – the number of necessary conditions aimed at phar-
maceutical security provision.
Results
Experts expressed their opinions, assessing the existence 
/ absence of the respective legal provision and / or the ex-
istence and failure or inefficiency of the existing provision. 
The opinions of all the experts coincided for 39 conditions 
(90.7%). The opinions of three experts (20%) were different 
for four legislative conditions of pharmaceutical security 
provision (1.5, 2.12, 3.8 and 3.9). Following the application 
of the Delphi method, a consensus was reached and the as-
Table 1
Conditions for pharmaceutical security provision
No Conditions for pharmaceutical security provision Legislative coverage
1 2 3
I. Ensuring efficiency, harmlessness and good quality of drugs
1.1. Conducting drug development research on ethical principles aimed at achieving health benefits; 0,5
1.2. Consistent and efficient operation of the authorisation procedure for drugs manufacturing in domestic enterprises; 1
1.3. Compliance with Good Practice Rules: GLP (good laboratory practice), GCP (good clinical practice), GMP (good 
manufacturing practice) for drugs;
0,5
1.4. Ensuring quality of drug substances and excipients used in the manufacture and preparation of drugs; 1
1.5. Consistent and efficient operation of the service of pharmacovigilance; 1
1.6. Ensuring transparency in the R&D process in the development of new drugs; 0
1.7. Ensuring the efficiency of the licensing process (expertise, approval, registration) of drugs marketing; 1
1.8. Ensuring the consistency and efficiency of the process of licensing drug imports; 1
1.9. Prevention of placing drugs not subject to quality control on the pharmaceutical market 1
1.10. Availability and continued application of measures to prevent the placement on the pharmaceutical market of 
counterfeit drugs
0
1.11. Ensuring consistent storage (GDP, GSP) and consistent transportation (GTP) of drugs. 0
II. Ensuring physical and economic availability of drugs
2.1. Uniform location of community drugstores throughout the country according to demographic and geographic rules; 0
2.2. Ensuring the presence of essential drugs, including compensated drugs in/at:
State drug nomenclature;
National Catalogue of manufacturer prices;
Drug storehouses;
Community drugstores;
Healthcare institutions (according to the Institutional Pharmaco-therapeutical Form and national clinical protocols).
0,5
2.3. Establishing accountability for the availability /lack of essential drugs in the pharmaceutical market; 0
2.4. Development and implementation of the orphan drugs concept; 0
2.5. Providing assistance with medications for people during the day and 24 hour-emergency assistance; 0
2.6. Providing full information regarding the availability /lack of drugs at community drugstores /drug storehouses; 0,5




Establishing a legal provision prohibiting unjustified refusal of drug delivery from the pharmaceutical storehouse to 
drugstores and medical institutions;
0
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sessment results coincided for the whole panel of experts 
(tab. 1, section 3).
The data provided at point 3, table 1 show the degree of 
legislative coverage of the conditions necessary for ensuring 
pharmaceutical security in the Republic of Moldova (tab. 2).
The data in table 2 indicate that the legislative coverage 
of the pharmaceutical security of the Republic of Moldova 
is insufficient. All the sectors need to be completed and re-
2.9. Existence of an efficient mechanism of drug pricing; 0,5
2.10. Providing professional negotiation of manufacturer prices; 0,5
2.11.
Ensuring effective functioning of the mechanism of drug public procurement for the needs of public medical institu-
tions;
0,5
2.12. Ensuring total transparency and excluding the conflict of interest from the process of public procurement of drugs; 0
2.13. Continuous extension of the list of compensated drugs; 0,5
2.14. Creation of incentive mechanisms for ensuring the availability of generic drugs on the pharmaceutical market. 0
III Ensuring good quality of pharmaceutical services and of good operation of the pharmaceutical system
3.1.
Ensuring compliance with essential pharmaceutical services (consistency with the accreditation standards and 
standard operating procedures)
0,5
3.2. Combating unfair competition in the pharmaceutical market, banning monopoly
3.3. Establishing enhancers for the implementation of advanced pharmaceutical services 0
3.4. Providing uninterrupted/timely information on the pharmaceutical act 0,5
3.5.
Ensuring the compliance with the requirements related to the professional level of specialists engaged in 
pharmaceutical activity
0
3.6. Compliance with standards of good pharmacy practice (GPP) and standards of good distribution practice (GDP) 0,5
3.7. Strengthening the functionality and efficiency of the Pharmaceutical Inspectorate 0,5
3.8. Regulating the principles of reasonable use of drugs 0
3.9. Streamlining the concept and the procedures for the accreditation of pharmaceutical enterprises; 0
3.10. Amending the procedure for authorising (licensing) the pharmaceutical activity and its professional strengthening; 0
3.11. Ensuring the compliance with the rules for the ethical promoting of drugs; 0
3.12.
Ensuring the prevention of conflicts of interest and of corruptibility in all processes, procedures and functions  com-
prised in the notion of pharmaceutical activity;
0
3.13. Strengthening the procedures for  the safe disposal of expired, refuse or deteriorated drugs; 1
3.14. Due exercise of the professions of pharmacist  and assistant pharmacist; 0,5
3.15.
Strengthening the role of professional organisations of pharmacists in order to ensure the high quality of 
pharmaceutical services and the smooth functioning of the entire pharmaceutical system;
0
3.16.
Establishing and promoting the principles for the collaboration between doctors and pharmacists to the benefit of 
the patient;
0
3.17. Effective contributions to the prevention and combating of  drug abuse and drug dealing; 0,5
3.18. Interaction regarding the development of all the dimensions of the clinical pharmacy concept.  0
quire new legal provisions, but the most poorly regulated 
is the quality of pharmaceutical services and the functio- 
ning of the pharmaceutical system as well as the ensuring the 
availability of drugs. The results obtained point to legislative 
gaps that affect the pharmaceutical security and may serve 
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Conclusions
1. The impact of the governmental factor in the Republic 
of Moldova concerning certain aspects of the pharmaceuti-
cal security was highlighted; 
2. The toolbox of methods for the analysis of the level 
of legislative coverage of pharmaceutical security was drawn 
up;
3. The insufficient legislative coverage of pharmaceutical 
security was proven and the legislative gaps related to phar-
maceutical security and, namely, the conditions necessary 
for its ensuring were pointed out: lacking – 20 rules; inef-
ficient or not complied with – 15 rules.
Table 2
Level of legislative coverage of the pharmaceutical security of the Republic of Moldova
Sectors
Legislative coverage







1. Ensuring efficiency, harmlessness and  high 
quality of drugs
6 3 2 7 6,63 moderate
2. Ensuring physical and economical 
availability of drugs 
- 7 7 3,5 2,50 insufficient
3. Ensuring the high quality of  pharmaceuti-
cal services and the smooth functioning of 
the pharmaceutical system  
1 10 6 4 2,22 insufficient
The entire system 7 20 15 14,5 3,37 insufficient
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